Fibrobiologics, Common Stock Stock Today
| FBLG Stock | 2.56 0.09 3.64% |
Performance9 of 100
| Odds Of DistressLess than 18
|
FibroBiologics, Common is trading at 2.56 as of the 28th of November 2024. This is a 3.64 percent up since the beginning of the trading day. The stock's lowest day price was 2.46. FibroBiologics, Common has less than a 18 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for FibroBiologics, Common Stock are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of August 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 31st of January 2024 | Category Healthcare | Classification Health Care |
FibroBiologics, Common is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 35.26 M outstanding shares of which 2.36 M shares are currently shorted by private and institutional investors with about 5.49 trading days to cover. More on FibroBiologics, Common Stock
Moving against FibroBiologics, Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
FibroBiologics, Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
FibroBiologics, Common can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand FibroBiologics, Common's financial leverage. It provides some insight into what part of FibroBiologics, Common's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
FibroBiologics, Common Stock (FBLG) is traded on NASDAQ Exchange in USA. It is located in 455 East Medical Center Boulevard, Houston, TX, United States, 77598 and employs 10 people. FibroBiologics, Common is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 114.94 M. FibroBiologics, Common conducts business under Biotechnology sector and is part of Health Care industry. The entity has 35.26 M outstanding shares of which 2.36 M shares are currently shorted by private and institutional investors with about 5.49 trading days to cover.
FibroBiologics, Common generates negative cash flow from operations
Check FibroBiologics, Common Probability Of Bankruptcy
Ownership AllocationFibroBiologics, Common holds a total of 35.26 Million outstanding shares. FibroBiologics, Common Stock retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check FibroBiologics, Ownership Details
FibroBiologics, Common Historical Income Statement
FibroBiologics, Stock Against Markets
FibroBiologics, Common Corporate Management
| Ruben JD | General Counsel | Profile | |
| Hamid Khoja | Chief Officer | Profile | |
| CFA CPA | Chief Officer | Profile | |
| Ruben Garcia | General Counsel | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroBiologics, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroBiologics, Common. If investors know FibroBiologics, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroBiologics, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.59) | Return On Assets (0.62) | Return On Equity (4.34) |
The market value of FibroBiologics, Common is measured differently than its book value, which is the value of FibroBiologics, that is recorded on the company's balance sheet. Investors also form their own opinion of FibroBiologics, Common's value that differs from its market value or its book value, called intrinsic value, which is FibroBiologics, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroBiologics, Common's market value can be influenced by many factors that don't directly affect FibroBiologics, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroBiologics, Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroBiologics, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroBiologics, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.